AWA
GSK icon

Arkadios Wealth Advisors’s GSK GSK Stock Holding History

Arkadios Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66M Sell
108,025
-1
-0% -$53 0.09% 240
2026
Q1 		$5.96M Buy
108,026
+647
+0.6% +$35.1K 0.1% 235
2025
Q4 		$5.27M Buy
107,379
+39,863
+59% +$1.86M 0.1% 214
2025
Q3 		$2.91M Sell
67,516
-1,244
-2% -$48.6K 0.07% 293
2025
Q2 		$2.64M Buy
68,760
+6,734
+11% +$257K 0.08% 273
2025
Q1 		$2.4M Buy
62,026
+7,468
+14% +$273K 0.09% 246
2024
Q4 		$1.85M Sell
54,558
-105
-0.2% -$3.78K 0.1% 198
2024
Q3 		$2.23M Sell
54,663
-406
-0.7% -$16.6K 0.13% 168
2024
Q2 		$2.12M Sell
55,069
-2,938
-5% -$124K 0.14% 156
2024
Q1 		$2.49M Sell
58,007
-147
-0.3% -$6.06K 0.19% 121
2023
Q4 		$2.16M Sell
58,154
-301
-0.5% -$10.8K 0.18% 122
2023
Q3 		$2.12M Sell
58,455
-712
-1% -$25.3K 0.2% 119
2023
Q2 		$2.11M Sell
59,167
-567
-0.9% -$20.3K 0.25% 100
2023
Q1 		$2.13M Sell
59,734
-3,902
-6% -$137K 0.25% 106
2022
Q4 		$1.55M Buy
63,636
+308
+0.5% +$10.3K 0.21% 122
2022
Q3 		$1.29M Buy
63,328
+4,984
+9% +$189K 0.2% 137
2022
Q2 		$3.17M Sell
58,344
-8
-0% -$442 0.47% 51
2022
Q1 		$3.18M Buy
58,352
+13,546
+30% +$736K 0.42% 57
2021
Q4 		$2.47M Sell
44,806
-711
-2% -$37K 0.33% 77
2021
Q3 		$2.17M Buy
45,517
+1,623
+4% +$81.5K 0.31% 84
2021
Q2 		$2.18M Buy
43,894
+41,290
+1,586% +$1.98M 0.27% 101
2021
Q1 		$116K Buy
2,604
+214
+9% +$9.71K 0.02% 505
2020
Q4 		$109K Buy
+2,390
New +$110K 0.02% 422
2020
Q2 		– Sell
-418
Closed -$19.8K – 1027
2020
Q1 		$19.8K Hold
418
– – 0.01% 489
2019
Q4 		$22.9K Buy
+418
New +$23.3K 0.01% 434

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arkadios Wealth Advisors's GSK Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its GSK (GSK) stake by 0% in Q2 2026, selling an estimated $53 and leaving 108,025 shares worth $5.66M. The position accounts for 0.09% of the portfolio, ranked #240.

Arkadios Wealth Advisors first reported a position in GSK in Q4 2019 and has held it in 25 quarters since. The position peaked at $5.96M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Arkadios Wealth Advisors held 108,025 shares of GSK worth $5.66M as of Q2 2026.
  • Arkadios Wealth Advisors sold 1 GSK share in Q2 2026, an estimated $53.
  • GSK made up 0.09% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #240 holding.
  • Arkadios Wealth Advisors first reported a position in GSK in Q4 2019 and has held it in 25 quarters since.
  • Arkadios Wealth Advisors's GSK position peaked at $5.96M in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.